Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | WNT3A | P56704 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18101284 | 0.94 | KDM4E (0.70) | TSHRKDM4EATMHPGDPKM | |
| SCHEMBL18101244 | 0.94 | KDM4E (0.70) | TSHRKDM4EATMHPGDPKM | |
| SCHEMBL18101240 | 0.94 | KDM4E (0.70) | TSHRKDM4EATMHPGDPKM | |
| SCHEMBL18101248 | 0.94 | KDM4E (0.70) | TSHRKDM4EATMHPGDPKM | |
| SCHEMBL1189145 | 0.92 | NPC1 (0.63) | TSHRKDM4EATMHPGDPKM | |
| SCHEMBL144609 | 0.88 | ALDH1A1 (0.69) | TSHRHPGDPKMCTNNB1NPSR1 | |
| SCHEMBL4824992 | 0.83 | NPSR1 (0.74) | TSHRKDM4EATMHPGDPKM | |
| SCHEMBL619634 | 0.82 | MAPK1 (0.78) | TSHRKDM4EATMHPGDPKM | |
| SCHEMBL1535157 | 0.81 | ATM (0.72) | TSHRKDM4EATMHPGDPKM | |
| SCHEMBL624490 | 0.80 | TSHR (1.00) | TSHRKDM4EATMHPGDPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220498-B2 | Neuroprotective aminothiazoles | DAHL RUSSELL (US) | 2022-01-11 | — | — | US | disclosed |
| WO-2021022061-A1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | OREGON STATE UNIVERSITY (US) | 2021-02-04 | — | — | WO | disclosed |
| EP-2906216-B1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | KUMAR AJAY (GB) | 2020-06-24 | — | — | EP | disclosed |
| US-20200190078-A1 | NEUROPROTECTIVE AMINOTHIAZOLES | DAHL RUSSELL (US) | 2020-06-18 | — | — | US | disclosed |
| EP-2781508-B9 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-2781508-B9 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-2781508-B1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO LTD (CN) | 2018-12-12 | — | — | EP | disclosed |
| US-10000521-B2 | Substituted gemcitabine bicyclic amide analogs and treatment methods using same | NUCORION PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000521-B2 | Substituted gemcitabine bicyclic amide analogs and treatment methods using same | NUCORION PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000521-B2 | Substituted gemcitabine bicyclic amide analogs and treatment methods using same | NUCORION PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2006-05-18 | — | — | US | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050215603-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES | 2005-09-29 | — | — | US | disclosed |
| US-20050209249-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005004818-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-5332735-A | Antiamnesic activity | ADIR ET COMPAGNIE (FR) | 1994-07-26 | — | — | US | disclosed |
| US-4937246-A | ABSORBED EASILY FROM INTESTINES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-06-26 | — | — | US | disclosed |
| EP-0318235-A2 | PAF antagonist, 1,4-disubstituted piperazine compounds and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1989-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190078-A1 | NEUROPROTECTIVE AMINOTHIAZOLES | PINK1, PSEN1, UCHL1 | TSHR 4402/4885KDM4E 1211/4885ATM 298/4885 |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | TSHR 738/4885KDM4E 4797/4885ATM 4220/4885 |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | TSHR 800/4885KDM4E 4690/4885ATM 4415/4885 |
| US-11220498-B2 | Neuroprotective aminothiazoles | PINK1, PSEN1, UCHL1 | TSHR 4402/4885KDM4E 1211/4885ATM 298/4885 |
| US-20050209249-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | TSHR 3528/4885KDM4E 1188/4885ATM 3169/4885 |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, PTGDR, LTB4R2 | TSHR 922/4885KDM4E 4782/4885ATM 4490/4885 |
| US-10000521-B2 | Substituted gemcitabine bicyclic amide analogs and treatment methods using same | TYMP, POLI, GOT1 | TSHR 3185/4885KDM4E 2005/4885ATM 845/4885 |
| US-20050215603-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | TSHR 3528/4885KDM4E 1188/4885ATM 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.